Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $110.55

Gilead Sciences, Inc. (NASDAQ:GILD) has earned a consensus recommendation of “Moderate Buy” from the twenty-seven brokerages that are currently covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $110.55.

GILD has been the topic of several recent analyst reports. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target on the stock. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company raised their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 22,929 shares of company stock worth $2,634,220 over the last quarter. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Matrix Trust Co lifted its holdings in shares of Gilead Sciences by 515.2% during the 4th quarter. Matrix Trust Co now owns 1,052 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 881 shares during the last quarter. Wedmont Private Capital increased its position in Gilead Sciences by 41.2% during the 4th quarter. Wedmont Private Capital now owns 13,481 shares of the biopharmaceutical company’s stock valued at $1,212,000 after buying an additional 3,931 shares in the last quarter. Pallas Capital Advisors LLC raised its stake in Gilead Sciences by 4.0% in the fourth quarter. Pallas Capital Advisors LLC now owns 8,150 shares of the biopharmaceutical company’s stock valued at $753,000 after buying an additional 314 shares during the last quarter. First Financial Corp IN purchased a new stake in Gilead Sciences in the fourth quarter valued at about $68,000. Finally, FNY Investment Advisers LLC acquired a new stake in Gilead Sciences in the fourth quarter worth about $471,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 2.8%

Shares of GILD opened at $109.11 on Wednesday. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a market cap of $135.73 billion, a P/E ratio of 294.89, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company’s fifty day simple moving average is $105.51 and its 200-day simple moving average is $100.02.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. The business’s revenue for the quarter was down .3% on a year-over-year basis. As a group, analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.